New delivery systems for hormonal contraception.
D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D009644:Norgestrel / Q000008:administration & dosage; D011247:Pregnancy; D011374:Progesterone / Q000008:administration & dosage; D011372:Progestins / Q000008:administration & dosage; D012106:Research; D013997:Time Factors; D014621:Vagina
D003271:Contraceptive Agents, Female; D004343:Drug Implants; D011372:Progestins; C016078:progestasert (progesterone-IUD); D009644:Norgestrel; D011374:Progesterone; D016912:Levonorgestrel; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; C024319:norethindrone enanthate; D009640:Norethindrone